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The efficient delivery of therapeutic genes into cells of interest is a critical challenge to broad application of
non-viral vector systems. In this research, a novel TPGS-b-(PCL-ran-PGA) nanoparticle modified with
polyethyleneimine was applied to be a vector of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
and endostatin for cervical cancer gene therapy. Firstly, a novel biodegradable copolymer, TPGS-b-(PCL-ran-PGA),
was synthesized and characterized. The nanoparticles were fabricated by an emulsion/solvent evaporation method
and then further modified with polyethyleneimine (PEI) carrying TRAIL and/or endostatin genes. The uptake of
pIRES2-EGFP and/or pDsRED nanoparticles by HeLa cells were observed by fluorescence microscopy and confocal
laser scanning microscopy. The cell viability of TRAIL/endostatin-loaded nanoparticles in HeLa cells was assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. Severe combined immunodeficient mice
carrying HeLa tumor xenografts were treated in groups of six including phosphate-buffered saline control, blank
TPGS-b-(PCL-ran-PGA) nanoparticles, blank TPGS-b-(PCL-ran-PGA)/PEI nanoparticles, and three types of gene
nanoparticles. The activity was assessed using average increase in survival time, body weight, and solid tumor
volume. All the specimens were then prepared as formalin-fixed and paraffin-embedded tissue sections for
hematoxylin-eosin staining. The data showed that the nanoparticles could efficiently deliver plasmids into HeLa
cells. The cytotoxicity of the HeLa cells was significantly increased by TRAIL/endostatin-loaded nanoparticles when
compared with control groups. The use of TPGS in combination with TRAIL and endostatin had synergistic
antitumor effects. In conclusion, the TRAIL/endostatin-loaded nanoparticles offer considerable potential as an ideal
candidate for in vivo cancer gene delivery.
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Cervical cancer caused by high-risk human papillomavirus
(HPV) infection constitutes a major problem in women's
health worldwide and is the fifth leading cause of cancer
deaths among females [1,2]. Current treatments including
surgery, chemotherapy, and radiotherapy remain to have
several disadvantages, thereby often leading to recurrence
[2]. Two prophylactic HPV vaccines (Gardasil and
Cervarix) [3] can prevent most high-risk HPV infections
and minimize the consequences of HPV-associated dis-
eases. However, these vaccines are effective only in adoles-
cents with no history of previous HPV infection and have
not shown any therapeutic effects against current HPV in-
fections or associated lesions [3]. Thus, there is an urgent
need to develop new specific drugs and methods to treat
cervical cancer. Tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) is a type 2 transmembrane pro-
tein that causes apoptosis of target cells through the
extrinsic apoptosis pathway. TRAIL belongs to a member
of the tumor necrosis factor superfamily including tumor
necrosis factor and Fas ligand [4]. The binding of tumor
necrosis factor and Fas ligand leads to the damage of
normal tissues in addition to their proapoptotic effect on
transformed cells [5,6], thus limiting their clinical applica-
tions. Conversely, TRAIL is able to selectively induce
apoptosis in transformed cells but not in most normal
cells [4,7,8], making it a promising candidate for tumor
therapy. Furthermore, tumor growth and progression rely
upon angiogenesis [9-11]. Consequently, antiangiogenesis
has also emerged as an attractive new strategy in the treat-
ment of cancer [12-16]. Among these agents, endostatin, a
20-kDa C-terminal proteolytic fragment of collagen XVIII,
has received the greatest attention [17]. It was found not
only to be a potent inhibitor of angiogenesis in vitro, but
also to have significant antitumor effects in a variety of
xenograft-based cancer models and clinical trials [17].
These promising results lead to the rapid advance of this
agent into the clinical test [17,18]. For instance, endostatin
enhanced the anticancer effect of CCRT in a mouse xeno-
graft model of cervical cancer [19]. Furthermore, the use
of endostatin in combination with other anticancer
agents such as gemcitabine had synergistic antitumor
activities [20].
Delivery of therapeutic agents by gene therapy has
been extensively studied in a broad range of diseases
[21-24]. However, a recurrent problem in these therapies
is the efficient delivery of the therapeutic DNA, RNA, or
siRNA to the target cells. The key technological impedi-
ment to successful gene therapy is vector optimization.
Thus, several strategies are being investigated to circum-
vent this problem such as adeno- or adeno-associated
viruses [25]. However, clinical trials have demonstrated
substantial obstacles to their use, such as immunogen-
icity and inflammatory potential [26]. Various non-viraldelivery systems, including liposomes [27], dendrimers
[28], polycationic polymers [29,30], and polymeric nano-
particles (NPs) [31] are under development to reduce or
avoid immunogenicity and associated risks of toxicity [32].
In recent years, the development of non-viral vectors
which could also increase transfection efficiency has
received great attention [33-38]. Among these vector sys-
tems, nanoparticles offer a number of advantages that
make them ideal candidates as vectors for specific gene
therapy. Furthermore, nanoparticles for gene therapy can
be simply prepared by conjugating DNA onto the nano-
particle surface. These nanoparticles could conveniently
enter into the cell via endocytosis [39-41]. Bioconjugate
techniques formed by the coating of cationic polymers
onto the surface of nanoparticles have been employed
for increasing the target gene complexing ability by regu-
lation of cationic polymers coated onto the nanoparticles
to optimize gene delivery [42-45]. To improve the trans-
fection of plasmid DNA (pDNA) into cells, negatively
charged pDNA and positively charged macromolecules
can be linked by charge interaction. Polyethyleneimine
(PEI), a representative cationic polymer, can be polyplexed
to pDNA, and these polyplexes have been successfully
used for gene transfection both in vitro and in vivo [46].
Although PEI is considered as one of the most efficient
non-viral gene transfer agents, it has some limitations due
to its cytotoxicity [47]. The hydrophilic polyethylene gly-
col (PEG) modification of PEI which was thought to create
a more non-ionic surface of polyplexes was previously
shown to reduce cytotoxicity [48].
In this research, a novel biodegradable diblock copoly-
mer, TPGS-b-(PCL-ran-PGA), was successfully synthe-
sized for nanoparticle formulation. We hypothesized that
TPGS-b-(PCL-ran-PGA) nanoparticles modified with a
polyplexed PEI could deliver TRAIL and/or endostatin to
the target cells to treat xenograft models bearing HeLa
cells. In the past decade, polycaprolactone (PCL) and its
copolymers were used in a number of drug delivery de-
vices. Due to the fact that PCL degrades at a slower rate
than polyglycolide (PGA), poly-D,L-lactide, and its copoly-
mers, it was therefore originally used in drug delivery
devices that remain active for over 1 year and in slowly
degrading suture materials [49]. Copolymerization of
ε-caprolactone (ε-CL) with other monomers or fast de-
grading polymers, i.e., malic acid and PGA, could facilitate
polymer degradation and control drug release. PGA is also
not a perfect biomaterial for use in drug delivery systems
[41]. The reason is that PGA has very high crystallinity
(45% to 55%), has high melting temperature (about
220°C), and is insoluble in general solvent. Diblock copol-
ymers and/or random copolymers offer the opportunity to
combine properties of different parent homopolymers in a
new material [2,41]. D-α-Tocopheryl polyethylene glycol
1000 succinate (TPGS), a water-soluble form of natural
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cinate with PEG 1000. It was reported that TPGS was
able to increase drug permeability through cell mem-
branes by downregulating expression of P-glycoprotein
(P-gp) and thus enhance absorption of drugs and re-
verse P-gp-mediated multidrug resistance in cancer cells
[50,51]. Furthermore, TPGS effectively inhibited the
growth of human lung carcinoma cells both in vitro and
in vivo [52]. The superior antitumor activity of TPGS
was associated with its increasing ability to induce
apoptosis [52-54]. Synergistic anticancer effects could
be obtained by the use of combinations of TPGS in the
presence of other anticancer agents [53].
Methods
Materials
TPGS, glycolide (1,4-dioxane-2,5-dione), and stannous
octoate were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Poly(vinyl alcohol) (PVA; 80% hydrolyzed),
branched polyethyleneimine (MW ~ 25,000), and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) were also purchased from Sigma-
Aldrich. ε-CL was from Acros Organics (Geel, Belgium).
40,6-Diamidino-2-phenylindole dihydrocloride (DAPI)
was obtained from VECTOR (Burlingame, CA, USA).
Plasmid vectors pShuttle2, pIRES2-EGFP, and pDsRED-
E1 were acquired from Invitrogen-Gibco (Carlsbad, CA,
USA). Dulbecco's modified Eagles' medium (DMEM),
fetal bovine serum (FBS), penicillin-streptomycin, and
Dulbecco's phosphate-buffered saline (DPBS) were also
from Invitrogen. All other chemicals and solvents used
were of the highest quality commercially available.
Synthesis and characterization of TPGS-b-(PCL-ran-PGA)
diblock copolymer
TPGS-b-(PCL-ran-PGA) diblock copolymers were syn-
thesized via ring opening copolymerization (ROP) of ε-CL,
glycolide, and TPGS as described previously [41]. Briefly,
weighted amounts of ε-CL, glycolide, and TPGS and one
drop of stannous octoate were added into a dried glass
ampoule. The ampoule was connected to a vacuum line,
evacuated, sealed off, and placed in oil bath at 160°C. A
slow and progressive viscosity increase of the bulk ho-
mogeneous mixture was always observed during the
polymerization, and the copolymers were produced in over
3 h. After cooling to room temperature, the ampoule was
opened, and the resulting copolymers were dissolved in
dichloromethane (DCM) and then precipitated in excess
cold methanol to remove unreacted TPGS and monomers.
The final product was collected by filtration and dried at
45°C under vacuum.
Fourier transform infrared spectroscopy (FT-IR) (Nicolet
Instrument Co., Madison, WI, USA) was employed to
investigate the chemical structure of TPGS-b-(PCL-ran-PGA) copolymer. Briefly, the samples for FT-IR ana-
lysis were prepared by grinding 99% potassium bromide
(KBr) with 1% copolymer and then pressing the mixture
into a transparent disk in an evacuable die at sufficiently
high pressure. The structure, number-averaged molecular
weight (Mn) of the copolymer, and copolymer composition
were determined by proton nuclear magnetic resonance
(1H NMR) in CDCl3 at 300 Hz (Bruker ACF300, Madison,
WI, USA). The weight-averaged molecular weight and
molecular weight distribution were determined by gel per-
meation chromatography (Waters, Milford, PA, USA).
Fabrication of TPGS-b-(PCL-ran-PGA) nanoparticles
The nanoparticles were fabricated by a multiple (W/O/W)
emulsion solvent evaporation method [55]. In brief, 50 mg
of TPGS-b-(PCL-ran-PGA) was emulsified with 2 ml
DCM by sonication for 30 s. After the addition of an
aqueous 6 ml of PVA solution (7% w/v), the emulsion was
sonicated again for 25 s. The resulting double emulsion
(W/O) was then poured into 100 ml of a 1% (w/v) PVA
solution containing 2% isopropanol and then maintained
under mechanical stirring for 1 h at 600 rpm. The residual
DCM was then dried under vacuum. Then, aliquots of the
nanoparticle suspension (1.8 ml) were washed twice with
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES)/NaOH (pH 7.0) by centrifugation (8,000
rpm, 10 min, 4°C) and then resuspended.
Preparation of expression vectors
Human TRAIL and endostatin were amplified by poly-
merase chain reaction (PCR) using primers: hendostatin-
F: 50-GCTCTAGAgccaccatgggaattcatgcacagccaccgcgactt
cc-30 (XbaІ), hendostatin-R: 50-GGGGTACCttacttggagg
cagtcatg-30 (KpnІ); hTRAIL-F: 50-GCTCTAGAgccaccat
ggtgagagaaagaggtcctcag-30 (XbaІ), hTRAIL-R: 50-GGG
GTACCttagccaactaaaaaggccc-30 (KpnІ). The enzyme was
digested and purified. PCR products were cloned into
pShuttle2 vector (Clontech, Mountain View, CA, USA). The
recombinant plasmids pShuttle2-TRAIL and pShuttle2-
endostatin were verified by enzyme digestion and DNA se-
quencing. Protein expression was analyzed by Western blot
as described below.
Nanoparticle modification
The nanoparticles were formulated with an N/P ratio (ratio
of the polymer nitrogen to the DNA phosphate) equal to
TPGS-b-(PCL-ran-PGA) nanoparticle solution (0.2 ml)
which was mixed with 2 mg of PEI in sterile HEPES-
buffered saline. The PEI-modified TPGS-b-(PCL-ran-PGA)
nanoparticle solution was then added to the plasmid DNA
solution at different N/P ratios and vortexed gently. The
pDNA-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles
were incubated for 20 min at room temperature in sterile
PBS.
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The mean particle size and size distribution were measured
by dynamic light scattering (Zetasizer Nano ZS90, Malvern
Instruments, Malvern, UK). One milligram of nanoparticles
was suspended in 3 ml of deionized (DI) water before
measurement. Zeta potential of the nanoparticles was de-
termined by laser Doppler anemometry (Zetasizer Nano
ZS90, Malvern Instruments, Malvern, UK). Samples were
prepared in PBS and diluted 1:3 with DI water to ensure
that the measurements were performed under conditions
of low ionic strength where the zeta potential of the
nanoparticles can be measured accurately. The final con-
centration of the polymer was 1 mg/ml. The data were
obtained with the average of three measurements. The par-
ticle morphology and size were examined by field emission
scanning electron microscopy (FESEM).
Loading efficiency of pDNA-loaded nanoparticles
The loading efficiency of pDNA-loaded nanoparticles was
evaluated by measuring the amount of free (unloaded)
pDNA in the nanoparticle solution. The TPGS-b-(PCL-
ran-PGA)/PEI nanoparticles were centrifuged, and the
supernatants were collected. DNA concentrations in the
supernatants were measured using a UV spectrophotom-
eter (Beckman, Fullerton, CA, USA) at 260 nm. Loading
efficiency of pDNA in the nanoparticles was determined
by subtracting the amount of pDNA recovered in the
supernatants from the initial amount of pDNA added.
In vitro release assay
To investigate the in vitro pDNA release, 5 mg of TPGS-
b-(PCL-ran-PGA)/PEI nanoparticles (group HNP) was
added in 1 ml of DPBS buffer (pH 7.4) and 25 mM so-
dium acetate buffer (pH 5.0), respectively, in an Eppendorf
tube and kept in a shaker at 37°C. Samples were periodic-
ally withdrawn from each tube and centrifuged at 15,000
rpm for 15 min to obtain pellet nanoparticles. The su-
pernatants were removed by aspiration and replaced with
fresh buffer solution, and the nanoparticles were resus-
pended by vortexing and repeated pipetting to break up
aggregated particles. The supernatants were kept at −40°C
until analysis by UV spectroscopy.
Gel retardation assay
Agarose gel electrophoresis was performed to determine
the binding of pDNA with TPGS-b-(PCL-ran-PGA)/PEI
nanoparticles. A series of different weight ratios (w/w) of
pDNA to TPGS-b-(PCL-ran-PGA)/PEI nanoparticles
was loaded on the agarose gel (10 ml of the sample
containing 0.1 mg of pDNA). A 1:6 dilution of loading
dye was added to each well, and electrophoresis was
performed at a constant voltage of 100 V for 20 min in
TBE buffer (4.45 mM Tris-base, 1 mM sodium EDTA,
4.45 mM boric acid, pH 8.3) containing 0.5 g/mlethidium bromide. The pDNA bands were then visual-
ized using a UV transilluminator at 365 nm.
Cell culture
HeLa cells (ATCC, Manassas, VA, USA) were cultured
in DMEM (pH 7.4) supplemented to contain 25 mM
NaHCO3, 10 μg/ml streptomycin sulfate, 100 μg/ml
penicillin G, and 10% (v/v) FBS. Cells were maintained
at 37°C in an incubator with 5% CO2 and 95% air.
Western blot
The cells were seeded into six-well tissue culture plates
and allowed to attach to the substrate overnight. The cells
were cultured at 37°C in an atmosphere of 5% CO2 in air
and then rinsed twice and preincubated for 1 h with 2 ml
of serum-free medium at 37°C. The recombinant plasmids
pShuttle2-TRAIL and pShuttle2-endostatin were added at
a particle concentration of 0.01 to 0.2 mg/ml and incu-
bated for 1 to 4 h at 37°C. The cells were then washed
three times with 1 ml ice-cold PBS (pH 7.4) to remove
any free pShuttle2-TRAIL or pShuttle2-endostatin. The
cells were continuously cultured in fresh complete me-
dium for 48 h. The cells were lysed in cell lysis buffer
containing PMSF for 30 min at 4°C. The lysate was then
centrifuged at 13,000 rpm for 20 min at 4°C. The proteins
were then separated by SDS-PAGE and transferred onto
PVDF membranes. The membranes were blocked in a
Tris-buffered saline with 0.1% Tween 20 (TBS-T) solution
with 5% (w/v) non-fat dry milk and incubated overnight
with primary antibodies at 4°C. The immunoreactive sig-
nals were detected with horseradish peroxidase-conjugated
secondary antibodies followed by SuperSignal West Pico
Chemiluminescent Substrate (Thermo Fisher Scientific,
Rockford, IL, USA). For protein loading control, mem-
branes were reprobed with anti-β-actin antibodies. For
the in vivo studies, tumors were harvested, and the
cell lysates were prepared and transferred to a clean
microcentrifuge tube and centrifuged at 14,000 rpm for
30 min. The supernatant was subjected to Western blot-
ting as described above.
Cellular uptake of fluorescent TPGS-b-(PCL-ran-PGA)/PEI
nanoparticles
The uptake of pIRES2-EGFP and/or pDsRED nano-
particles by HeLa cells were firstly observed by fluores-
cence microscopy. In brief, cells were preincubated in
serum-free medium at 37°C for 1 h and then for 2 h in the
presence of pIRES2-EGFP or pDsRED gene-loaded
TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (final particle
concentration, 0.2 mg/ml). The samples were mounted
in fluorescent mounting medium, and the fluorescence
was observed under a fluorescence microscope (Leica
DMI6000 B, Wetzlar, Germany).
Figure 1 FT-IR spectra of TPGS and TPGS-b-(PCL-ran-PGA)
copolymer.
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cells were preincubated in serum-free medium at 37°C for
1 h and then for 2 h in the presence of pIRES2-EGFP-
loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (final
particle concentration, 0.2 mg/ml). The cells were rinsed
three times with cold PBS and then fixed by ethanol for 20
min. The nuclei were stained with DAPI for 30 min and
washed twice with PBS. Finally, the cells were observed
using a confocal laser scanning microscope (Fluoview FV-
1000, Olympus Optical Co., Ltd., Tokyo, Japan).
Cell viability
The cytotoxicity of gene nanoparticles was evaluated by
the MTT assay. Briefly, HeLa cells were seeded at a
density of 5 × 103 cells/well in 100-μl culture medium
into a 96-well plate and incubated overnight. The cells
were incubated with various gene nanoparticles at 40
μg/ml nanoparticle concentration for 24 and 48 h, re-
spectively. At designated time intervals, the medium was
removed and 20 μl/well of 5 mg/ml MTT solution was
added to each well. After 4 h of incubation at 37°C
under a humidified atmosphere supplemented with 5%
CO2 in air, MTT was taken up by active cells and re-
duced in the mitochondria to form insoluble purple
formazan granules. Subsequently, the medium was dis-
carded and the precipitated formazan was dissolved in
dimethyl sulfoxide (150 ml/well), and optical density of
the resulting solution was evaluated using a microplate
spectrophotometer at a wavelength of 570 nm. The ana-
lytical assays were performed every day, and at least four
wells were randomly taken for examination each time to
determine viability based on the physical and biochem-
ical properties of cells.
In vivo studies
Female severe combined immunodeficient (SCID) mice
of 15 to 20 g were provided by the Medical Experimental
Animal Center of Guangdong Province (Guangzhou,
China). Animal experiments were conducted under the
protocol approved by the Institutional Animal Care and
Use Committee of Tsinghua University. A subcutaneous
xenograft nude mouse model was established. Six-week-
old female nude mice (body weight = 18 ± 2 g) were in-
oculated subcutaneously with 1.5 to 2 × 106 HeLa cells.
When the average size of tumors reached approximately
100 mm3, the mice were randomly divided into six
groups consisting of six mice each: PBS control, blank
TPGS-b-(PCL-ran-PGA) nanoparticles (group DNP),
blank TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group
ENP), TRAIL-loaded TPGS-b-(PCL-ran-PGA)/PEI na-
noparticles (group FNP), endostatin-loaded TPGS-
b-(PCL-ran-PGA)/PEI nanoparticles (group GNP), and
TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/
PEI nanoparticles (group HNP). Each mouse in thetreatment groups received a single dose of nanoparticles
equivalent to 0.2 mg TPGS-b-(PCL-ran-PGA), 10 μg PEI,
and 50 μg DNA (for TRAIL- or endostatin-loaded TPGS-
b-(PCL-ran-PGA)/PEI nanoparticles, the amount of
pDNA was equivalent to the amount of pShuttle2-TRAIL
or endostatin plus pShuttle2). The groups were treated
once every week with intratumoral injections of either
PBS or gene nanoparticles. Tumor size was measured
using a caliper, and the weight of each mouse was mea-
sured with a scale every 3 days until the end of the experi-
ment. Tumor volume was calculated using the following
formula: volume = length × width2/2. The mean tumor
volume was used to construct a tumor growth curve to
evaluate the therapeutic efficacy of gene nanoparticles.
Tumor specimens were then prepared as formalin-fixed,
paraffin-embedded sections for hematoxylin-eosin (H&E)
staining.
Statistical analyses
All experiments were repeated at least three times unless
otherwise stated. T test statistical analysis was performed
with SPSS 16.0 software (Chicago, IL, USA), with P <
0.05 considered to indicate a significant difference.
Results and discussion
Characterization of TPGS-b-(PCL-ran-PGA) diblock
copolymer
The TPGS-b-(PCL-ran-PGA) diblock copolymer was
successfully synthesized via ROP. FT-IR spectra of the
TPGS-b-(PCL-ran-PGA) copolymer and TPGS are
shown in Figure 1. The carbonyl band of TPGS was ob-
served at 1,739 cm−1. For the TPGS-b-(PCL-ran-PGA)
copolymer, the carbonyl band was shifted to 1,736 cm−1,
which was also different with the carbonyl bands of
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[56,57]. All the C-H stretching bonds are centered at
2,949 and 2,867 cm−1 [56]. The absorption bands from
3,400 to 3,650 cm−1 are due to the terminal OH group,
and that at 1,045 to 1,295 cm−1 is attributed to the C-O
stretching [58]. Of those, the absorption bands from 1,105
to 1,242 cm−1 are attributed to the characteristic C-O-C
stretching vibrations of the repeated -OCH2CH2 units of
TPGS and the -COO bond stretching vibrations of GA
and CL, respectively [56]. The band at 1,295 cm−1 has
been used to investigate the crystallinity change in PCL
[2]. All these signals indicate the TPGS-b-(PCL-ran-PGA)
copolymer may be formed. The chemical structure of
TPGS-b-(PCL-ran-PGA) copolymer is shown in Figure 2A.
In order to further confirm the formation of the random
copolymer, the 1H NMR spectrum is recorded and is
shown in Figure 2B. The peak at 3.65 ppm (Figure 2,
peak e) could be attributed to the -CH2 protons of the
PEO part of TPGS [2,41]. The lower signals in the ali-
phatic zone belong to various moieties of vitamin E tails
[2,41]. Peaks at 1.39 (h), 1.67 (g), 2.31 to 2.44 (f ), and
4.06 ppm (d) are assigned to methylene protons in PCL
units, respectively [2,41]. The difference between the
two peaks at 4.06 (c) and 4.16 ppm (b) which indicated
that two kinds of copolymers would be obtained was
reasonable (shown in Figure 2). Furthermore, it was
from the appearance of the two different peaks that we
could conclude that both GA and CL monomers had
copolymerized with TPGS monomers. The characteristic
signal at 4.62 to 4.82 ppm (a) exists, which is attributed to
the methylene (CH2) protons of the PGA units [41]. The
molecular weight of the TPGS-b-(PCL-ran-PGA) copoly-
mer was calculated by the use of the ratio between the peak
areas at 4.06, 4.62 to 4.82, and 3.65 ppm. The Mn of the
TPGS-b-(PCL-ran-PGA) copolymer was estimated to beFigure 2 Chemical structure (A) and typical 1H NMR spectra (B) of TPG23,852. The Mn calculated from the gel permeation chro-
matograph was 25,811. It seemed that the molecular weight
measured from NMR and GPC can confirm each other.
Construction and expression of pShuttle2-TRAIL and
pShuttle2-endostatin
Recombinant plasmids pShuttle2-TRAIL and pShuttle2-
endostatin were verified by enzyme digestion and DNA
sequencing. Protein expression of TRAIL and endostatin
was analyzed by Western blot using cell lysate after trans-
fection of HeLa cells using PEI (Figure 3). These results
showed that pShuttle2-TRAIL and pShuttle2-endostatin
were successfully constructed and expressed in HeLa cells.
Characterization of nanoparticles
The effect of PEI modification on particle size was deter-
mined by dynamic light scattering (DLS; Table 1). The
average hydrodynamic diameter of the polyplexed PEI/
pDNA nanoparticles (CNP) was 83 nm, whereas the
diameters of the unmodified TPGS-b-(PCL-ran-PGA)
nanoparticles (DNP) and PEI-modified TPGS-b-(PCL-
ran-PGA) nanoparticles (HNP) were approximately 215
and approximately 273 nm, respectively (Figure 4A). In
addition, the surface charge (zeta potential) of the nano-
particles was determined by laser Doppler anemometry
(Zetasizer Nano ZS90, Malvern Instruments, Malvern,
UK; Table 1 and Figure 4B). Surface modification of
the TPGS-b-(PCL-ran-PGA) nanoparticles significantly
changed the zeta potential, suggesting that the negative
surface charge of the TPGS-b-(PCL-ran-PGA) nano-
particles (DNP) was changed to a positive charge with PEI
modification. Consistent with these results, a reduction
in the positive charge for control PEI/TPGS-b-(PCL-
ran-PGA) nanoparticles (ENP) was obtained because
the TPGS-b-(PCL-ran-PGA) nanoparticles (DNP) wasS-b-(PCL-ran-PGA) copolymer.
Figure 3 Western blot analysis of recombined pShuttle2-endostatin and pShuttle2-TRAIL expression in 293 T cells. Control: 293 T cells
transfected by pShuttle2. rE: 293 T cells transfected by pShuttle2-endostatin. rT: 293 T cells transfected by pShuttle2-TRAIL.
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ability of all TPGS-b-(PCL-ran-PGA)/PEI nanoparticles
to immobilize pDNA was confirmed by agrose gel electro-
phoresis (Figure 4C). In a recent report, the pDNA
complexed to the polymeric (poly(lactic-co-glycolic acid
(PLGA)) nanoparticles is in a condensed form, which
could protect it against denaturation and allow to be
efficiently taken up by MSCs. In addition, PLGA/PEI
nanoparticles possessed the ability to condense DNA
for protection against degradation [55]. Table 1 also
shows the loading efficiencies of all PEI-modified gene
nanoparticles (groups FNP, GNP, and HNP) which were
above 60%.
Surface morphology of the PEI-modified TPGS-b-
(PCL-ran-PGA) nanoparticles was observed by FESEM.
Figure 4D shows a typical FESEM image of the TPGS-b-
(PCL-ran-PGA)/PEI nanoparticles. The morphologies
of PEI-modified TPGS-b-(PCL-ran-PGA) particles were
sphere-like nanoparticles in shape. The FESEM image
further confirmed the particle size detected from DLS.Table 1 Characterization of nanoparticles
Group Size (nm) Polydispersion Zeta potential (mV) Lo
(n = 3) (n = 3)
ANP 72.11 ± 3.44 0.164 22.54 ± 3.47
BNP 71.82 ± 5.18 0.156 21.58 ± 4.16
CNP 83.02 ± 2.35 0.178 24.65 ± 2.78
DNP 215.06 ± 3.52 0.186 −18.25 ± 2.36
ENP 236.31 ± 1.44 0.201 23.65 ± 3.65
FNP 265.48 ± 4.40 0.229 19.45 ± 1.99
GNP 245.48 ± 6.42 0.215 18.45 ± 2.67
HNP 272.97 ± 4.68 0.245 16.54 ± 1.06In vitro release
The timing of nanoparticle degradation and DNA re-
lease appears to have a significant modulating impact on
the gene expression [59]. We compared the in vitro
release of pDNA from PEI-modified TPGS-b-(PCL-ran-
PGA) nanoparticles at pH 5.0 and pH 7.4. pDNA release
was determined by measuring UV absorption at 260 nm
at specific time points. The data showed that 40.5% of
the loaded pDNA was released rapidly from PEI-
modified TPGS-b-(PCL-ran-PGA) nanoparticles within
48 h at pH 7.4, followed by sustained release until day 8
(Figure 5). This fact may be due to the dependency of
the TPGS-b-(PCL-ran-PGA) degradation on the external
conditions. It was reported that at low pH values, cleav-
age of the ester linkage of the polyester backbone such
as PLGA was catalyzed to accelerate the polymer deg-
radation. However, at pH 7.4, the release kinetics of
pDNA was similar with that at pH 5.0. PEI, which is a
hydrophilic molecule located at the surface of the
TPGS-b-(PCL-ran-PGA) matrix, may hasten degradationading efficiency (%) Gene Polymer
(n = 3)
83.4 ± 2.3 TRAIL PEI
82.6 ± 1.9 Endostatin PEI
78.3 ± 3.8 TRAIL/endostatin PEI
0 None TPGS-b-(PCL-ran-PGA)
0 None PEI/TPGS-b-(PCL-ran-PGA)
67.4 ± 4.3 TRAIL PEI/TPGS-b-(PCL-ran-PGA)
64.6 ± 3.1 Endostatin PEI/TPGS-b-(PCL-ran-PGA)
62.5 ± 0.9 TRAIL/endostatin PEI/TPGS-b-(PCL-ran-PGA)
Figure 4 Effects of PEI modification, binding of pDNA with TPGS-b-(PCL-ran-PGA)/PEI nanoparticles, and FESEM image of HNP. (A) The
effects of PEI modification on particle size. (B) The effects of PEI modification on surface charge. (C) The binding of pDNA with TPGS-b-(PCL-ran-
PGA)/PEI nanoparticles determined by agarose gel electrophoresis. A series of different weight ratios (w/w) of pDNA to TPGS-b-(PCL-ran-PGA)/PEI
nanoparticles was loaded on the agarose gel (a, pDNA/NPs = 1:0; b, pDNA/NPs = 1:4; c, pDNA/NPs = 1:10; d, pDNA/NPs = 1:20; e, pDNA/NPs =
1:20; f, pDNA/NPs = 1:20). (D) FESEM image of TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (HNP).
Zheng et al. Nanoscale Research Letters 2013, 8:161 Page 8 of 12
http://www.nanoscalereslett.com/content/8/1/161of the nanoparticles by increasing hydration and thereby
promoting hydrolysis [30].
Cellular uptake of TPGS-b-(PCL-ran-PGA)/PEI nanoparticles
To determine cellular uptake of nanoparticles, HeLa cells
were incubated with TPGS-b-(PCL-ran-PGA)/PEI nano-
particles. Figure 6 shows the fluorescence imaging of
HeLa cells after incubation with pIRES2-EGFP-loaded
and pDsRED-loaded TPGS-b-(PCL-ran-PGA)/PEI nano-
particles. As can be seen in Figure 6, HeLa cells showedFigure 5 In vitro release profile of TRAIL- and endostatin-
loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles at pH 7.4
and 5.0.strong green (Figure 6B) and red (Figure 6C) fluorescence,
indicating that pIRES2-EGFP-loaded and pDsRED-loaded
TPGS-b-(PCL-ran-PGA)/PEI nanoparticles could be effi-
ciently internalized into the cells.
CLSM images showed that the fluorescence of the
pIRES2-EGFP-loaded TPGS-b-(PCL-ran-PGA)/PEI nano-
particles (green) was located around the entire cell inclu-
ding the nucleus area (blue, stained by DAPI) (Figure 6D,
E,F), which further confirmed that the nanoparticles could
efficiently deliver plasmids into HeLa cells.
Cell viability of gene nanoparticles
Cytotoxicity of all gene nanoparticles (groups FNP, GNP,
and HNP), blank TPGS-b-(PCL-ran-PGA) nanoparticles
(group DNP), and blank TPGS-b-(PCL-ran-PGA)/PEI
nanoparticles (group ENP) was compared to that of PBS
by the MTT assay. Figure 7 shows the in vitro viability of
HeLa cells cultured with various nanoparticles (groups
DNP, ENP, FNP, GNP, and HNP) and PBS (n = 5) after
24- and 48-h incubation. The results showed that all
gene-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles
appeared to have significant cytotoxicity than other
control nanoparticles (P < 0.05). Especially, TRAIL- and
endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nano-
particles (group HNP) had much more cytotoxicity (P <
0.01). The higher cytotoxicity of TRAIL- and endostatin-
loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group
HNP) may be attributed to synergistic antitumor effects of
TRAIL and endostatin and the degradation and release of
Figure 6 Fluorescence and confocal laser scanning microscopy images of HeLa cells after incubation. (A to C) The fluorescence
microscopy images of HeLa cells after incubation with pIRES2-EGFP-loaded and pDsRED-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles. (D to F)
Confocal laser scanning microscopy images of HeLa cells after incubation with pIRES2-EGFP-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles at
37.0°C. The cells were stained by DAPI (blue), and the pIRES2-EGFP-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles are in green. The cellular
uptake was visualized by overlaying images obtained using DAPI filter and FITC filter: (D) from DAPI channel, (E) from FITC channel, (F) from
combined DAPI channel and FITC channel.
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that the superior antitumor activity of TPGS was due
to its increasing ability to induce apoptosis [52-54].
Synergistic antitumor activities could be obtained by
the use of combinations of TPGS and other anticancer
drugs [53].Figure 7 Viability of HeLa cells cultured with various
nanoparticles in comparison with that of PBS. After 24- and 48-h
incubation. (n = 5).In vivo studies
The antitumor efficacy of all gene nanoparticles (groups
FNP, GNP, and HNP) was further evaluated on SCID
mice of an average body weight of approximately 17.8 g
and an average initial tumor volume of approximately
103 mm3. The data showed that the mean survival time
of mice treated with TRAIL/endostatin-loaded nano-
particles was significantly longer than that of the control
mice, whereas body weight among these groups had no
statistical difference (P > 0.05). The average tumor
growth volume was shown in Figure 7 in comparison
with those of the PBS control, blank TPGS-b-(PCL-
ran-PGA) nanoparticles (group DNP), and blank TPGS-
b-(PCL-ran-PGA)/PEI nanoparticles (group ENP). It can
be seen from Figure 8 that TRAIL- and endostatin-loaded
TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group HNP)
significantly slowed down the tumor growth of mice in
comparison with the PBS control and other nanoparticles.
Compared with the PBS control, blank TPGS-b-(PCL-
ran-PGA) nanoparticles (group DNP) could also have
slight anticancer efficacy. This phenomenon may be due
to the degradation and release of TPGS from the TPGS-b-
(PCL-ran-PGA) copolymer. It was reported that TPGS
could also have superior anticancer efficacy by inducing
apoptosis [52-54]. By considering the overall slope of all
the curves in Figure 8, it can be concluded that the
TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/
Figure 8 Antitumor effect of various nanoparticles in
comparison with that of PBS.
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tages than controls and single gene-loaded nanoparticles
(groups FNP and GNP) in suppressing tumors. Thus, we
could conclude that synergistic antitumor activities
could be obtained by the use of combinations of TRAIL,
endostatin, and TPGS. As shown in Figure 9, the images
of H&E staining also indicated that tumor growth
treated by TRAIL- and endostatin-loaded TPGS-b-
(PCL-ran-PGA)/PEI nanoparticles (group HNP) was
significantly inhibited in comparison with that of the
PBS control. In conclusion, the TRAIL/endostatin-Figure 9 Representative H&E staining of tumors. Treated with PBS (A),
loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (C), and TRAIL and endostaloaded nanoparticles offer considerable potential as an
ideal candidate for in vivo cancer gene delivery.
In future studies, we will investigate the combined effect
of TRAIL/endostatin gene therapy and chemotherapeutic
agents such as doxorubicin, docetaxel, and floxuridine, en-
capsulated in TPGS-b-(PCL-ran-PGA) nanoparticles, in
different cervical cancer cell lines and animal models in
order to make clear whether a combination of TRAIL/
endostatin gene therapy and chemotherapy will have en-
hanced antitumor activity. We hypothesize that surface
modification of TPGS-b-(PCL-ran-PGA) nanoparticles
with polyethyleneimine may also be a promising and use-
ful drug and gene co-delivery system.
Conclusions
For the first time, a novel TPGS-b-(PCL-ran-PGA) nano-
particle modified with polyethyleneimine was applied to be
a vector of TRAIL and endostatin for cervical cancer gene
therapy. The data showed that the nanoparticles could effi-
ciently deliver plasmids into HeLa cells and the expression
of TRAIL and endostatin was verified by RT-PCR and
Western blot analysis. The cytotoxicity of the HeLa cells
was significantly increased by TRAIL/endostatin-loaded
nanoparticles when compared with control groups. Syner-
gistic antitumor activities could be obtained by the use of
combinations of TRAIL, endostatin, and TPGS. The im-
ages of H&E staining also indicated that tumor growth
treated by TRAIL- and endostatin-loaded TPGS-b-(PCL-
ran-PGA)/PEI nanoparticles was significantly inhibited inTRAIL-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (B), endostatin-
tin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (D).
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the TRAIL/endostatin-loaded nanoparticles offer consider-
able potential as an ideal candidate for in vivo cancer gene
delivery.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YZ carried out the in vivo studies and drafted the manuscript. HC carried out
the cell studies. XZ carried out the preparation of nanoparticles. YoZ carried
out the characterization of nanoparticles. XX carried out the in vitro drug
release studies. ZL participated in the in vivo studies. DG participated in the
design of the study and performed the statistical analysis. LM conceived of
the study and participated in its design and coordination. All authors read
and approved the final manuscript.
Acknowledgements
The authors gratefully acknowledge the financial support from the Natural
Science Foundation of Guangdong Province (S2012010010046), Science,
Technology and Innovation Commission of Shenzhen Municipality
(JC200903180532A, JC200903180531A, JC201005270308A,
KQC201105310021A, and JCYJ20120614191936420), Doctoral Fund of
Ministry of Education of China (20090002120055), Nanshan District Bureau of
Science and Technology, National Natural Science Foundation of China
(31270019, 51203085), and Program for New Century Excellent Talents in
University (NCET-11-0275).
Author details
1The Shenzhen Key Lab of Gene and Antibody Therapy, Center for
Biotechnology and BioMedicine and Division of Life Science and Health,
Graduate School at Shenzhen, Tsinghua University, L401, Tsinghua Campus,
Xili University Town, Shenzhen, Guangdong Province 518055, People's
Republic of China. 2School of Life Sciences, Tsinghua University, Beijing
100084, People's Republic of China. 3School of Medicine, Shenzhen
University, Shenzhen 518060, People's Republic of China. 4Institute of Disease
Control and Prevention, Shenzhen Entry-Exit Inspection and Quarantine
Bureau, Shenzhen 518045, People's Republic of China.
Received: 26 October 2012 Accepted: 17 January 2013
Published: 9 April 2013
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden:
Globocan 2000. Int J Cancer 2001, 94:153–156.
2. Ma Y, Huang L, Song C, Zeng X, Liu G, Mei L: Nanoparticle formulation of
poly(ε-caprolactone-co-lactide)-d-α-tocopheryl polyethylene glycol 1000
succinate random copolymer for cervical cancer treatment. Polymer 2010,
51:5952–5959.
3. Schiller JT, Castellsague X, Villa LL, Hildesheim A: An update of prophylactic
human papillomavirus L1 virus-like particle vaccine clinical trial results.
Vaccine 2008, 26(Suppl 10):K53–K61.
4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland
GR, Smith TD, Rauch C, Smith CA, Goodwin RG: Identification and
characterization of a new member of the TNF family that induces
apoptosis. Immunity 1995, 3:673–682.
5. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T,
Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody
in mice. Nature 1993, 364:806–809.
6. Nagata S: Apoptosis by death factor. Cell 1997, 88:355–365.
7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C,
Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris
L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor
activity of recombinant soluble Apo2 ligand. J Clin Invest 1999,
104:155–162.
8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J,
Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC,
Lynch DH: Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157–163.9. Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med
1971, 285:1182–1186.
10. Folkman J: Tumor angiogenesis and tissue factor. Nat Med 1996, 2:167–168.
11. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol
Therapeut 1994, 63:265–311.
12. Winlaw DS: Angiogenesis in the pathobiology and treatment of vascular
and malignant diseases. Ann Thorac Surg 1997, 64:1204–1211.
13. Folkman J: Is angiogenesis an organizing principle in biology and
medicine? J Pediatr Surg 2007, 42:1–11.
14. Folkman J: Antiangiogenesis in cancer therapy-endostatin and its
mechanisms of action. Exp Cell Res 2006, 312:594–607.
15. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat
Rev Drug Discov 2007, 6:273–286.
16. Michael SO: Antiangiogenesis and vascular endothelial growth factor/
vascular endothelial growth factor receptor targeting as part of a
combined-modality approach to the treatment of cancer. Int J Radiat
Oncol Biol Phys 2007, 69:S64–S66.
17. Zhuang HQ, Yuan ZY: Process in the mechanisms of endostatin
combined with radiotherapy. Cancer Lett 2009, 282(1):9–13.
18. Herbst RS, Lee AT, Tran HT, Abbruzzese JL: Clinical studies of angiogenesis
inhibitors: the University of Texas MD Anderson Center Trial of Human
Endostatin. Curr Oncol Rep 2001, 3:131–140.
19. Jia Y, Liu M, Cao L, Zhao X, Wu J, Lu F, Li Y, He Y, Ren S, Ju Y, Wang Y, Li Z:
Recombinant human endostatin, Endostar, enhances the effects of
chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J
Gynaecol Oncol 2011, 32(3):316–324.
20. Wu Y, Yang L, Hu B, Liu JY, Su JM, Luo Y, Ding ZY, Niu T, Li Q, Xie XJ, Wen
YJ, Tian L, Kan B, Mao YQ, Wei YQ: Synergistic anti-tumor effect of
recombinant human endostatin adenovirus combined with gemcitabine.
Anticancer Drugs 2005, 16(5):551–557.
21. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR,
Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M,
Thrasher AJ, Thrasher AZ, Ylä-Herttuala S: Progress and prospects: gene
therapy clinical trials (part 1). Gene Ther 2007, 20:1439–1447.
22. Guinn BA, Mulherkar R: International progress in cancer gene therapy.
Cancer Gene Ther 2008, 12:765–775.
23. Scherer L, Rossi JJ, Weinberg MS: Progress and prospects: RNA-based
therapies for treatment of HIV infection. Gene Ther 2007, 14:1057–1064.
24. Androic I, Krämer A, Yan R, Rödel F, Gätje R, Kaufmann M, Strebhardt K,
Yuan J: Targeting cyclin B1 inhibits proliferation and sensitizes breast
cancer cells to taxol. BMC Cancer 2008, 8:391.
25. Brun A, Albina E, Barret T, Chapman DA, Czub M, Dixon LK, Keil GM,
Klonjkowski B, Le Potier MF, Libeau G, Ortego J, Richardson J, Takamatsu
HH: Antigen delivery systems for veterinary vaccine development.
Viral-vector based delivery systems. Vaccine 2007, 26:6508–6528.
26. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM: Chitosan-coated
PLGA nanoparticles for DNA/RNA delivery: effect of the formulation
parameters on complexation and transfection of antisense
oligonucleotides. Nanomedicine 2007, 3:173–183.
27. Geusens B, Lambert J, De Smedt SC, Buyens K, Sanders NN, Van Gele M:
Ultradeformable cationic liposomes for delivery of small interfering RNA
(siRNA) into human primary melanocytes. J Control Release 2009, 133:214–220.
28. Zhou J, Wu J, Hafdi N, Behr JP, Erbacher P, Peng L: PAMAM dendrimers for
efficient siRNA delivery and potent gene silencing. Chem Commun 2006,
22:2362–2364.
29. Park TG, Jeong JH, Kim SW: Current status of polymeric gene delivery
systems. Adv Drug Deliv Rev 2006, 58:467–486.
30. Son S, Kim WJ: Biodegradable nanoparticles modified by branched
polyethylenimine for plasmid DNA delivery. Biomaterials 2010, 31:133–143.
31. Blum JS, Saltzman WM: High loading efficiency and tunable release of
plasmid DNA encapsulated in submicron particles fabricated from PLGA
conjugated with poly-L-lysine. J Control Release 2008, 129:66–72.
32. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate
TD, Klatzmann D, Lassmann H, Castro MG, Löwenstein PR: Chronic brain
inflammation and persistent herpes simplex virus 1 thymidine kinase
expression in survivors of syngeneic glioma treated by adenovirus mediated
gene therapy: implications for clinical trials. Nat Med 1999, 11:1256–1263.
33. Huang H, Yu H, Tang G, Wang Q, Li J: Low molecular weight
polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin
coupled to peptide targeting HER2 as a gene delivery vector.
Biomaterials 2010, 31(7):1830–1838.
Zheng et al. Nanoscale Research Letters 2013, 8:161 Page 12 of 12
http://www.nanoscalereslett.com/content/8/1/16134. Haase R, Argyros O, Wong SP, Harbottle RP, Lipps HJ, Ogris M, Magnusson T,
Vizoso Pinto MG, Haas J, Baiker A: pEPito: a significantly improved non-
viral episomal expression vector for mammalian cells. BMC Biotechnol
2010, 10:20.
35. Halama A, Kuliński M, Librowski T, Lochyński S: Polymer-based non-viral
gene delivery as a concept for the treatment of cancer. Pharmacol Rep
2009, 61(6):993–999.
36. Keeney M, van den Beucken JJ, van der Kraan PM, Jansen JA, Pandit A: The
ability of a collagen/calcium phosphate scaffold to act as its own vector
for gene delivery and to promote bone formation via transfection with
VEGF (165). Biomaterials 2010, 31(10):2893–2902.
37. Mei L, Jin X, Song C, Wang M, Levy RJ: Immobolization of gene vector on
polyurethane using monoclonal antibody for localized gene delivery.
J Gene Med 2006, 8:690–698.
38. Jin X, Mei L, Song C, Liu L, Leng X, Sun H, Kong D, Levy RJ: Immobilization
of plasmid DNA on anti-DNA antibody modified coronary stent for
intravascular site-specific gene therapy. J Gene Med 2008, 10(4):421–429.
39. Uchimura E, Yamada S, Uebersax L, Fujita S, Miyake M, Miyake J: Method for
reverse transfection using gold colloid as a nano-scaffold. J Biosci Bioeng
2007, 103(1):101–103.
40. Hauck TS, Ghazani AA, Chan WC: Assessing the effect of surface chemistry
on gold nanorod uptake, toxicity, and gene expression in mammalian
cells. Small 2008, 4(1):153–159.
41. Huang L, Chen H, Zheng Y, Song X, Liu R, Liu K, Zeng X, Mei L:
Nanoformulation of d-.alpha;-tocopheryl polyethylene glycol 1000
succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for
breast cancer therapy. Integr Biol 2011, 3:993–1002.
42. Andersen MØ, Lichawska A, Arpanaei A, Rask Jensen SM, Kaur H, Oupicky D,
Besenbacher F, Kingshott P, Kjems J, Howard KA: Surface functionalisation of
PLGA nanoparticles for gene silencing. Biomaterials 2010, 31(21):5671–5677.
43. Kakade S, Manickam DS, Handa H, Mao G, Oupický D: Transfection activity
of layer-by-layer plasmid DNA/poly(ethylenimine) films deposited on
PLGA microparticles. Int J Pharm 2009, 365:44–52.
44. Matsumoto A, Kitazawa T, Murata J, Horikiri Y, Yamahara H: A novel
preparation method for PLGA microspheres using non-halogenated
solvent. J Control Release 2008, 129:223–227.
45. Chumakova OV, Liopo AV, Andreev VG, Cicenaite I, Evers BM, Chakrabarty S,
Pappas TC, Esenaliev RO: Composition of PLGA and PEI/DNA
nanoparticles improves ultrasound-mediated gene delivery in solid
tumor in vivo. Cancer Lett 2008, 261:215–225.
46. Zeng X, Sun YX, Qu W, Zhang XZ, Zhuo RX: Biotinylated transferrin/avidin/
biotinylated disulfide containing PEI bioconjugates mediated p53 gene
delivery system for tumor targeted transfection. Biomaterials 2010,
31(17):4771–4780.
47. Peng L, Gao Y, Xue YN, Huang SW, Zhuo RX: Cytotoxicity and in vivo
tissue compatibility of poly(amidoamine) with pendant aminobutyl
group as a gene delivery vector. Biomaterials 2010, 31(16):4467–4476.
48. Beyerle A, Braun A, Merkel O, Koch F, Kissel T, Stoeger T: Comparative
in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary
delivery in mice. J Control Release 2011, 151(1):51–56.
49. Sun H, Mei L, Song C, Cui X, Wang P: The in vivo degradation, absorption
and excretion of PCL-based implant. Biomaterials 2006, 27:1735–1740.
50. Collnot EM, Baldes C, Wempe MF, Kappl R, Hüttermann J, Hyatt JA, Edgar KJ,
Schaefer UF, Lehr CM: Mechanism of inhibition of P-glycoprotein
mediated efflux by vitamin E TPGS: influence on ATPase activity and
membrane fluidity. Mol Pharm 2007, 4(3):465–474.
51. Zhang Z, Mei L, Feng SS: Vitamin E D-α-tocopheryl polyethylene glycol
1000 succinate-based nanomedicine. Nanomedicine 2012,
7(11):1645–1647.
52. Youk HJ, Lee E, Choi MK, Lee YJ, Chung JH, Kim SH, Lee CH, Lim SJ:
Enhanced anticancer efficacy of alpha-tocopheryl succinate by
conjugation with polyethylene glycol. J Control Release 2005, 107:43–52.
53. Constantinou C, Papas A, Constantinou AI: Vitamin E and cancer: an
insight into the anticancer activities of vitamin E isomers and analogs.
Int J Cancer 2008, 123(4):739–752.
54. Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K,
Salvatore BA, Ralph SJ: Vitamin E analogs, a novel group of “mitocans”, as
anticancer agents: the importance of being redox-silent. Mol Pharmacol
2007, 71(5):1185–1199.
55. Kim JH, Park JS, Yang HN, Woo DG, Jeon SY, Do HJ, Lim HY, Kim JM, Park
KH: The use of biodegradable PLGA nanoparticles to mediate SOX9 genedelivery in human mesenchymal stem cells (hMSCs) and induce
chondrogenesis. Biomaterials 2011, 32:268–278.
56. Zhou S, Xu J, Yang H, Deng X: Synthesis and characterization of
biodegradable poly(ε-caprolactone)-polyglycolide-poly(ethylene glycol)
monomethyl ether random copolymer. Macromol Mater Eng 2004,
289:576–580.
57. Song CX, Sun HF, Feng XD: Microspheres of biodegradable block
copolymer for long-acting controlled delivery of contraceptives.
Polymer J 1987, 19:485–491.
58. Liu K, Kiran E: High-pressure solution blending of poly(ε-caprolactone)
with poly(methyl methacrylate) in acetone plus carbon dioxide.
Polymer 2008, 49:1555–1561.
59. Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, Eisen HN, Heller J,
Langer R, Putnam D: Molecularly engineered poly (ortho ester)
microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004,
3:190–196.
doi:10.1186/1556-276X-8-161
Cite this article as: Zheng et al.: Surface modification of TPGS-b-(PCL-
ran-PGA) nanoparticles with polyethyleneimine as a
co-delivery system of TRAIL and endostatin for cervical cancer gene
therapy. Nanoscale Research Letters 2013 8:161.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
